3Hanefeld M, Bounter K P, Dikision S, et al. Rapid and short - acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care, 2000, 23(2) :202.
4Hu S, Wang S, Fanelli B, et al. Pancreatic beta-cell K(ATP) channel activity and membrane - binding studies with nateglinide: a comparison with sulfonylureas and repaglinide. J Pharmacol Exp Ther, 2000, 293 (2) :444.
5Uehino H, Niwa M, Shimizu T, et al. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogueo Endocr J, 2000, 47 (5) : 639.
6World Health Organization.Definition,Diagnosis and Classification of Diabetes Mellitus and its Complications:Report of a WHO Consultation.Partl:Diagnosis and Classification of Diabetes Mellitus.Geneva,World Health Org,1999:1.
7World Health Organization.Country and regional data.Availableat; http://www.who.int/diabetes/facta/world.figures/cn/.
8Louis M,Helene L,Claude C.Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients:Variations with increasing levels of HbA1c.Diabetes Care,2003,26:881.
9Kikichi M.Modulation of insulin secretion in non-insulin-dependent diabetes mellitusby two novel oral hypoglycaemic agents,NN623 and A4166.Diabet Med,1996,13:S151.
10Yki-Jarvinen H,Dressier A,Ziemen M,H0E901/3002 Study Group:Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compare with bedtime NPH insulin during combination therapy in type 2 diabetes.Diabetes Care,2000,23:1130.
